Tenon Medical Inc (TNON) Stock Analysis
Verdict: AVOID
Relentless cash burn and serial warrant dilution offset Catamaran revenue growth, making TNON an extreme-risk trading vehicle.
Investment score: 20/100
Analysis as of
Is Tenon Medical Inc stock worth reviewing? AI model thesis
The model views TNON as a high-risk microcap with chronic capital needs; despite recent Q2 revenue growth (+127% YoY to $1.28M), operational cash drain forces continuous dilutive financing.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 15/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Tenon Medical Inc opportunities and risks
What speaks for TNON
- Catamaran System Revenue Acceleration
What speaks against TNON
- Unending Equity Dilution and Warrant Overhang
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| TNON | n/a | 0.4x | n/a | 66.3% | -256.3% | -594.7% |
| NVNO | n/a | 0.0x | n/a | 0.0% | 0.0% | -269.8% |
| IVF | n/a | 0.2x | n/a | 33.3% | -70.2% | -295.8% |
| XAIR | n/a | 0.3x | 0.0x | 4.2% | -435.7% | -985.5% |
| BJDX | n/a | 0.0x | 1.2x | 0.0% | 0.0% | -705.3% |
| Peer median | n/a | 0.1x | n/a | 2.1% | -35.1% | -500.5% |
Frequently asked questions about Tenon Medical Inc (TNON)
Is TNON stock a good investment?
The cached TradeMates AI model rates Tenon Medical Inc as AVOID with an investment score of 20/100. The model views TNON as a high-risk microcap with chronic capital needs; despite recent Q2 revenue growth (+127% YoY to $1.28M), operational cash drain forces continuous dilutive financing. This is algorithmic model output, not personal investment advice.
Is TNON stock a buy?
The TradeMates model verdict for TNON is AVOID with an investment score of 20/100. Treat this as a model signal to review, not a personal buy recommendation.